CN110546146B - 作为血浆激肽释放酶抑制剂的杂芳基羧酰胺衍生物 - Google Patents

作为血浆激肽释放酶抑制剂的杂芳基羧酰胺衍生物 Download PDF

Info

Publication number
CN110546146B
CN110546146B CN201880026013.2A CN201880026013A CN110546146B CN 110546146 B CN110546146 B CN 110546146B CN 201880026013 A CN201880026013 A CN 201880026013A CN 110546146 B CN110546146 B CN 110546146B
Authority
CN
China
Prior art keywords
group
methyl
pharmaceutically acceptable
acceptable salt
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880026013.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN110546146A (zh
Inventor
S·弗拉蒂尼
I·林加德
D·W·汉普雷克
R·A·巴克尔
M·埃克哈特
A·戈尔纳
J·P·赫恩
E·兰格普夫
H·瓦格纳
B·韦伦佐
D·维登梅尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN110546146A publication Critical patent/CN110546146A/zh
Application granted granted Critical
Publication of CN110546146B publication Critical patent/CN110546146B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201880026013.2A 2017-04-21 2018-04-16 作为血浆激肽释放酶抑制剂的杂芳基羧酰胺衍生物 Active CN110546146B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17167549.9 2017-04-21
EP17167549 2017-04-21
PCT/EP2018/059633 WO2018192866A1 (en) 2017-04-21 2018-04-16 Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors

Publications (2)

Publication Number Publication Date
CN110546146A CN110546146A (zh) 2019-12-06
CN110546146B true CN110546146B (zh) 2023-02-21

Family

ID=58606127

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880026013.2A Active CN110546146B (zh) 2017-04-21 2018-04-16 作为血浆激肽释放酶抑制剂的杂芳基羧酰胺衍生物

Country Status (7)

Country Link
US (1) US10501440B2 (enExample)
EP (1) EP3612523B1 (enExample)
JP (1) JP7175914B2 (enExample)
CN (1) CN110546146B (enExample)
AR (1) AR111414A1 (enExample)
TW (1) TW201902887A (enExample)
WO (1) WO2018192866A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12091399B2 (en) 2018-10-10 2024-09-17 Boehringer Ingelheim International Gmbh Phenyltetrazole derivatives as plasma kallikrein inhibitors
TW202144331A (zh) 2020-02-13 2021-12-01 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
TWI873290B (zh) 2020-02-13 2025-02-21 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
JP7773522B2 (ja) * 2020-07-10 2025-11-19 メルク・シャープ・アンド・ドーム・エルエルシー 血漿カリクレイン阻害薬
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013111108A1 (en) * 2012-01-27 2013-08-01 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
CN105452240A (zh) * 2013-05-23 2016-03-30 卡尔维斯塔制药有限公司 杂环衍生物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103687795B (zh) 2011-07-21 2016-05-11 蒂森克虏伯系统工程股份有限公司 用于在传送装置上停止和/或对准运输货物的器件和方法以及传送装置
WO2017072021A1 (en) 2015-10-27 2017-05-04 Boehringer Ingelheim International Gmbh Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013111108A1 (en) * 2012-01-27 2013-08-01 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
CN105452240A (zh) * 2013-05-23 2016-03-30 卡尔维斯塔制药有限公司 杂环衍生物

Also Published As

Publication number Publication date
AR111414A1 (es) 2019-07-10
TW201902887A (zh) 2019-01-16
JP7175914B2 (ja) 2022-11-21
US10501440B2 (en) 2019-12-10
WO2018192866A1 (en) 2018-10-25
EP3612523B1 (en) 2021-06-09
JP2020517619A (ja) 2020-06-18
CN110546146A (zh) 2019-12-06
US20180305339A1 (en) 2018-10-25
EP3612523A1 (en) 2020-02-26

Similar Documents

Publication Publication Date Title
CN110546146B (zh) 作为血浆激肽释放酶抑制剂的杂芳基羧酰胺衍生物
JP6855477B2 (ja) 血漿カリクレイン阻害薬としてのヘテロアリールカルボキサミド誘導体
EP3368529B1 (en) Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
JP5752232B2 (ja) プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物
JP6828191B2 (ja) 血漿カリクレイン阻害剤としての複素芳香族カルボキサミド誘導体
JP7703587B2 (ja) 血漿カリクレイン阻害剤としての複素芳香族カルボキシアミド誘導体
CN112752757B (zh) 作为rho-激酶抑制剂的酪氨酸酰胺衍生物
JP7686002B2 (ja) 血漿カリクレイン阻害剤としての複素芳香族カルボキサミド誘導体
JP7378470B2 (ja) 血漿カリクレイン阻害剤としてのフェニルテトラゾール誘導体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant